During an appearance in South Carolina over the weekend, Hillary Clinton endorsed amending marijuana from it’s current Schedule I classification, reserved for the most dangerous of drugs, to Schedule II, a lesser classification intended for drugs that have recognized medical applications but also have a high potential for abuse and severe psychological or physical dependence.
The presidential candidate said, “What I do want is for us to support research into medical marijuana because a lot more states have passed medical marijuana than have legalized marijuana, so we’ve got two different experiences or even experiments going on right now. And the problem with medical marijuana is there’s a lot of anecdotal evidence about how well it works for certain conditions, but we haven’t done any research. Why? Because it’s considered what’s called a Schedule I drug, and you can’t even do research on it.”
Let’s take a look at these statements a little more closely.
First, Clinton’s claim that “we haven’t done any research” on cannabis’ safety and potential efficacy is false. NORML documents hundreds of relevant trials here. Clinton’s allegation is further rebutted by the findings of a 2012 review of FDA-approved clinical trials involving the use of herbal cannabis in various patient populations, “Based on evidence currently available the Schedule I classification is not tenable; it is not accurate that cannabis has no medical value, or that information on safety is lacking.”
Second, while Clinton’s comments mark an evolution in her position on marijuana policy, she is late to the game among the presidential candidates proposing policy solutions to marijuana’s prohibition. Fellow democrat presidential candidate, Martin O’Malley previously pledged to use his executive authority, if elected, to move marijuana from Schedule I to Schedule II. And Republican presidential candidate Rand Paul is a sponsor of the CARERS Act, legislation that, among other things, would also move marijuana from Schedule I to Schedule II.
Third, while all of these statements by presidential candidates is a step in the right direction, NORML has and will continue to advocate for marijuana’s removal from the federal Controlled Substances Act. Rescheduling marijuana from I to II would not limit the federal government’s authority to prosecute marijuana offenders, including those who are in compliance with state law, nor would it likely stimulate clinical trial research trials beyond those studies funded by the US National Institute on Drug Abuse and reliant upon government-grown marijuana.
Fortunately, Vermont Senator and Democrat Presidential candidate, Bernie Sanders has introduced legislation to remove marijuana from the US Federal Controlled Substances Act. The Ending Federal Marijuana Prohibition Act of 2015 would deschedule cannabis from the CSA, similar to alcohol and tobacco. It would also allow states the power to establish their own marijuana policies and banking policies free from federal interference.
Reform advocates can contact their member of the US Senate in support of The Ending Federal Marijuana Prohibition Act of 2015 by clicking here.